Beijing Tiantan Biological Products Co., Ltd. (referred to as "Tiantan Biological Products") is engaged in vaccines, blood products, diagnostics and other biological products research, production and management of enterprises in 1998 by Beijing Institute of Biological Products (formerly the Northern Government in 1919 established the Central Disease Control, is the cradle of Chinese biological products) in launching the Shanghai Stock Exchange listing, is now the controlling shareholder China National Pharmaceutical Group Corporation. With the development of the company now has Changchun Biological Products Co., Ltd. Chi Kin, a number of apheresis plasma subsidiary companies.

Tiantan Biological Products has 110 kinds of products, including hepatitis B vaccine, polio vaccine, MMR vaccine, encephalitis vaccine, influenza vaccine, chickenpox vaccine, human serum albumin, intravenous immunoglobulin other varieties, is an important national immunization program vaccine production base.

market years, the company accumulated dividends 477 million yuan, total assets, the main income, total profits have achieved 400%growth. Company in 2006 - 2008 for three consecutive years the "Golden Round Table Award for outstanding board of directors' award, won the 10th (2007) China's listed companies" Golden Bull Award hundred shareholder return, "and other awards.